JOHNSON & JOHNSON is 10.1x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($573.98 B vs $56.80 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | REGN | JNJ |
|---|---|---|
| Market cap | $56.80 B | $573.98 B |
| US-listed rank | #292 | #20 |
| Revenue (latest FY) | $14.34B | $94.19B |
| Net income (latest FY) | $4.50B | $26.80B |
| Net margin | 31.4% | 28.5% |
| P/E (trailing FY) | 12.6 | 21.4 |
| SEC filings | 985 | 984 |
JOHNSON & JOHNSON is 10.1x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($573.98 B vs $56.80 B).
In their latest fiscal years, REGENERON PHARMACEUTICALS, INC. reported $14.34B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: REGENERON PHARMACEUTICALS, INC. and JOHNSON & JOHNSON, or browse the full rankings.